See Whole Prescribing Data OPDIVO® (nivolumab) is indicated for the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed right after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or immediately after three or more traces of systemic therapy that features autologou